Abeona Therapeutics (ABEO) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Surrozen (SRZN) has outperformed Abeona Therapeutics (ABEO) over the past year, gaining 82.9% versus a loss of 3.2%. Over five years, SRZN leads with a -73.5% price change compared with -77.7% for ABEO. Abeona Therapeutics is the larger company by market cap ($284.0 million vs $277.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABEO | SRZN |
|---|---|---|
| Share price | $4.97 | $23.58 |
| Market cap | $283.95M | $277.15M |
| 1-day change | -2.25% | -6.22% |
| YTD return | -3.61% | +11.26% |
| 1-year return | -3.24% | +82.87% |
| 5-year return | -77.67% | -73.48% |
| EPS (TTM) | $-1.18 | $-39.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.65 | $37.83 |
| 52-week low | $4.00 | $11.39 |
| Distance from 52-week high | -35.09% | -37.67% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +280.22% | +105.26% |
| Average volume | 1.41M | 475.02K |
| Shares outstanding | 57.18M | 11.75M |
| Employees | 226 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed ABEO by 86.1 percentage points over the past year.
About Abeona Therapeutics
ABEO stock →Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
ABEO vs SRZN FAQ
Which is bigger, Abeona Therapeutics or Surrozen?
Abeona Therapeutics (ABEO) is larger, with a market capitalization of $283.95M compared with $277.15M for Surrozen (SRZN).
Which stock has performed better over the past year, ABEO or SRZN?
SRZN returned +82.87% over the past 12 months, compared with -3.24% for ABEO (price return, excluding dividends). Past performance does not predict future results.
Are Abeona Therapeutics and Surrozen in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Abeona Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Surrozen.